Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 375

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 375
---
(58,050)$29.37 — $— (58,050)$29.37 Nonvested, December 31, 2024324,685 $28.80 20,000 $28.63 344,685 $28.79 The total aggregate grant date fair value of PSUs that vested during the years ended December 31, 2024, 2023, and 2022 were $3.9 million, $4.1 million, and $1.0 million, respectively. Performance-Based AwardsThe performance-based PSU awards require certain performance targets to be achieved in order to vest. Vesting is also subject to continued service requirements through the date the achievement of the performance target is certified. As of December 31, 2024, the total unrecognized compensation expense was $6.1 million. The Company expects to prospectively recognize these expenses over a weighted-average period of 0.8 years.Market-Based AwardsThe market-based PSU awards are subject to achievement of market-based performance targets in order to vest. The Company used a Monte-Carlo Simulation to determine the fair value and expected term of the awards as of grant date. There was no unrecognized compensation expense as of December 31, 2024. The expected term of the awards granted in 2021 was 0.9 years.

10. Earnings per Share

Basic earnings per share (EPS) is calculated using the weighted average number of common shares outstanding. Diluted EPS is calculated using the weighted average number of common shares outstanding, including the dilutive effect of the Company’s stock options, stock awards, and employee stock purchase plan (ESPP) awards using the treasury-stock method, and the 2023 Notes using the if-converted method.

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)10. Earnings per Share (Continued)

The following table sets forth the computation of basic and diluted EPS for the years ended December 31, 2024, 2023 and 2022 (dollars in thousands, except share and per share amounts): Year Ended December 31,202420232022Numerator:Net earnings$73,865 $1,316 $60,711 After-tax interest expense for 2023 Notes— — 3,556 Numerator for dilutive earnings per share$73,865 $1,316 $64,267 Denominator